FDA Inspection 1235622 — Temple University Hospital Bone Marrow Transplant Program
The FDA completed an inspection of Temple University Hospital Bone Marrow Transplant Program on Apr 2, 2024 in Philadelphia, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 2, 2024
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Philadelphia, PA (United States)